Signature Medical is developing AcoustiCare, its flagship wearable product focused on heart failure evaluation and monitoring to improve patient outcomes while preventing hospital re-admissions.
It differs from other typical sensor-based wearables with its proprietary cloud-based audio technology and artificial intelligence enabling remote monitoring and evaluation of heart failure and other indications.
Proceeds from this financing will be used to accelerate the development and commercialization of the AcoustiCare system.
Signature Medical offers innovative solutions focused on value-based healthcare initially focused on heart failure. It is dedicated to improving outcomes while reducing costs in high-value, large underserved markets using proprietary cloud-based and wearable technology.
Riot is an early-stage venture fund that invests in emerging technologies such as artificial intelligence, internet of things, autonomous vehicles, robotics, and augmented and virtual reality. Riot is headquartered in Boston with offices in Los Angeles.
Bose Corp. invests in long-term research with one fundamental goal: to develop new technologies with real customer benefits. Bose innovations have spanned decades and industries, creating and transforming categories in audio and beyond.
NeuroSense Therapeutics reports Phase 2b trial results of PrimeC in ALS
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
LynxKite Technologies expands Biophytis collaboration
BioDlink named 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Excellence Awards
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
Emerald Clinical Trials honoured with 2026 Asia Pacific Biopharma Excellence Award
Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004
Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial
Avene partners with BotDesign to advance clinical studies in dermo-cosmetics
AnaCardio secures US patent for AC01, extending protection until 2042
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan